ID   SFRP2_CANLF             Reviewed;         294 AA.
AC   Q863H1;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   03-AUG-2022, entry version 101.
DE   RecName: Full=Secreted frizzled-related protein 2;
DE            Short=sFRP-2;
DE   Flags: Precursor;
GN   Name=SFRP2;
OS   Canis lupus familiaris (Dog) (Canis familiaris).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Laurasiatheria; Carnivora; Caniformia; Canidae; Canis.
OX   NCBI_TaxID=9615;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Irish setter; TISSUE=Retina;
RX   PubMed=14999144; DOI=10.1023/b:brea.0000018412.83348.ff;
RA   Lee J.L., Chang C.J., Wu S.Y., Sargan D.R., Lin C.T.;
RT   "Secreted frizzled-related protein 2 (SFRP2) is highly expressed in canine
RT   mammary gland tumors but not in normal mammary glands.";
RL   Breast Cancer Res. Treat. 84:139-149(2004).
CC   -!- FUNCTION: Soluble frizzled-related proteins (sFRPS) function as
CC       modulators of Wnt signaling through direct interaction with Wnts. They
CC       have a role in regulating cell growth and differentiation in specific
CC       cell types. SFRP2 may be important for eye retinal development and for
CC       myogenesis.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- INDUCTION: Up-regulated in mammary gland tumors.
CC   -!- DOMAIN: The FZ domain is involved in binding with Wnt ligands.
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the secreted frizzled-related protein (sFRP)
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ560716; CAD90762.1; -; mRNA.
DR   RefSeq; NP_001002987.1; NM_001002987.2.
DR   AlphaFoldDB; Q863H1; -.
DR   SMR; Q863H1; -.
DR   CORUM; Q863H1; -.
DR   STRING; 9615.ENSCAFP00000012270; -.
DR   MEROPS; I93.002; -.
DR   PaxDb; Q863H1; -.
DR   Ensembl; ENSCAFT00000013260; ENSCAFP00000012270; ENSCAFG00000008353.
DR   Ensembl; ENSCAFT00030016702; ENSCAFP00030014595; ENSCAFG00030009035.
DR   Ensembl; ENSCAFT00030016877; ENSCAFP00030014750; ENSCAFG00030009035.
DR   Ensembl; ENSCAFT00040022516; ENSCAFP00040019510; ENSCAFG00040012203.
DR   Ensembl; ENSCAFT00040022642; ENSCAFP00040019619; ENSCAFG00040012203.
DR   Ensembl; ENSCAFT00845016668; ENSCAFP00845012972; ENSCAFG00845009450.
DR   GeneID; 475471; -.
DR   CTD; 6423; -.
DR   VEuPathDB; HostDB:ENSCAFG00845009450; -.
DR   VGNC; VGNC:46081; SFRP2.
DR   eggNOG; KOG3577; Eukaryota.
DR   GeneTree; ENSGT00940000156432; -.
DR   InParanoid; Q863H1; -.
DR   OrthoDB; 1306779at2759; -.
DR   Proteomes; UP000002254; Chromosome 15.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0061133; F:endopeptidase activator activity; IEA:Ensembl.
DR   GO; GO:0001968; F:fibronectin binding; IPI:BHF-UCL.
DR   GO; GO:0005178; F:integrin binding; IDA:BHF-UCL.
DR   GO; GO:0048018; F:receptor ligand activity; IEA:Ensembl.
DR   GO; GO:0017147; F:Wnt-protein binding; IBA:GO_Central.
DR   GO; GO:0030509; P:BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IBA:GO_Central.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; IEA:Ensembl.
DR   GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0007267; P:cell-cell signaling; IDA:BHF-UCL.
DR   GO; GO:0031668; P:cellular response to extracellular stimulus; IEA:Ensembl.
DR   GO; GO:0071481; P:cellular response to X-ray; IEA:Ensembl.
DR   GO; GO:0002063; P:chondrocyte development; IEA:Ensembl.
DR   GO; GO:0030199; P:collagen fibril organization; IEA:Ensembl.
DR   GO; GO:0060028; P:convergent extension involved in axis elongation; IEA:Ensembl.
DR   GO; GO:0048546; P:digestive tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0071425; P:hematopoietic stem cell proliferation; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0007501; P:mesodermal cell fate specification; IEA:Ensembl.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IBA:GO_Central.
DR   GO; GO:0010667; P:negative regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0030308; P:negative regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0030336; P:negative regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0061185; P:negative regulation of dermatome development; IEA:Ensembl.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IEA:Ensembl.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:1902230; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage; IDA:BHF-UCL.
DR   GO; GO:0043508; P:negative regulation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:0042662; P:negative regulation of mesodermal cell fate specification; IEA:Ensembl.
DR   GO; GO:0050732; P:negative regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:2000041; P:negative regulation of planar cell polarity pathway involved in axis elongation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0003402; P:planar cell polarity pathway involved in axis elongation; IEA:Ensembl.
DR   GO; GO:0090179; P:planar cell polarity pathway involved in neural tube closure; IEA:Ensembl.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; IDA:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:1904956; P:regulation of midbrain dopaminergic neuron differentiation; IEA:Ensembl.
DR   GO; GO:0010975; P:regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:2000035; P:regulation of stem cell division; IEA:Ensembl.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0061056; P:sclerotome development; IEA:Ensembl.
DR   GO; GO:0048866; P:stem cell fate specification; IEA:Ensembl.
DR   GO; GO:0090244; P:Wnt signaling pathway involved in somitogenesis; IEA:Ensembl.
DR   CDD; cd07446; CRD_SFRP2; 1.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   Gene3D; 2.40.50.120; -; 1.
DR   InterPro; IPR015526; Frizzled/SFRP.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR036790; Frizzled_dom_sf.
DR   InterPro; IPR001134; Netrin_domain.
DR   InterPro; IPR018933; Netrin_module_non-TIMP.
DR   InterPro; IPR026558; SFRP2.
DR   InterPro; IPR041764; SFRP2_CRD.
DR   InterPro; IPR008993; TIMP-like_OB-fold.
DR   PANTHER; PTHR11309; PTHR11309; 1.
DR   PANTHER; PTHR11309:SF45; PTHR11309:SF45; 1.
DR   Pfam; PF01392; Fz; 1.
DR   Pfam; PF01759; NTR; 1.
DR   SMART; SM00643; C345C; 1.
DR   SMART; SM00063; FRI; 1.
DR   SUPFAM; SSF50242; SSF50242; 1.
DR   SUPFAM; SSF63501; SSF63501; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50189; NTR; 1.
PE   2: Evidence at transcript level;
KW   Developmental protein; Differentiation; Disulfide bond; Reference proteome;
KW   Secreted; Signal; Wnt signaling pathway.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000255"
FT   CHAIN           25..294
FT                   /note="Secreted frizzled-related protein 2"
FT                   /id="PRO_0000032541"
FT   DOMAIN          34..154
FT                   /note="FZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DOMAIN          171..294
FT                   /note="NTR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00295"
FT   DISULFID        39..102
FT                   /evidence="ECO:0000250"
FT   DISULFID        49..95
FT                   /evidence="ECO:0000250"
FT   DISULFID        86..124
FT                   /evidence="ECO:0000250"
FT   DISULFID        113..151
FT                   /evidence="ECO:0000250"
FT   DISULFID        117..141
FT                   /evidence="ECO:0000250"
FT   DISULFID        171..244
FT                   /evidence="ECO:0000250"
FT   DISULFID        174..246
FT                   /evidence="ECO:0000250"
FT   DISULFID        189..294
FT                   /evidence="ECO:0000250"
SQ   SEQUENCE   294 AA;  33340 MW;  79C1FF3882CBE1B1 CRC64;
     MPRGPGSLLL LVLASHCCLG SARGLFFGQP DFSYKRSNCK PIPANLQLCH GIEYQNMRLP
     NLLGHETMKE VLEQAGAWIP LVMKQCHPDT KKFLCSLFAP VCLDDLDETI QPCHSLCVQV
     KDRCAPVMSA FGFPWPDMLE CDRFPQDNDL CIPLASSDHL LPATEEAPKV CEACKNKNED
     DNDIMETLCK NDFALKIKVK EITYINRDTK IILETKSKTI YKLNGVSERD LKKSVLWLKD
     SLQCTCEEMN DINAPYLVMG QKLGGELVIT SVKRWQKGQR EFKRISRSIR KLQC